The U.S. regenerative medicine market is anticipated to grow at compound annual growth rate of more than 33 percent through 2022, based on an Orbis Research analysis, according to medGadget.
Here are four observations:
1. The increasing interest in tissue-engineered and stem cell products will boost the market's growth.
2. Regenerative medicines' potential in restoring diseased organs will elevate the market.
3. Cell therapy captured 80 percent of the U.S. regenerative medicine market in 2015.
4. Dominate market vendors include Acelity, Mesoblast, Organogenesis, Reprocell and Stryker.